Clinical Trials Browser

Phase 4 × Recurrence × tislelizumab × Clear all

NCT06761911 2025-01-07

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

Phase 4 Not yet recruiting

Hodgkin Disease, Recurrence